ASRT250117P3000
- 1.95
- 0.000.00%
Assertio Newsroom
Assertio Therapeutics Announces Leadership Changes and Board Addition
Express News | Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
Press Release: Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
H.C. Wainwright Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $4
HC Wainwright & Co. Reiterates Buy on Assertio Holdings, Maintains $4 Price Target
Promising Buy Rating for Assertio Therapeutics Backed by Positive ROLVEDON Trial Results and Market Potential
Executive Reshuffles: JPM, QCOM, DVN and LTC
Assertio Announces Results Of A Clinical Trial Investigating The Utility Of Rolvedon Injection When Dosed The Same Day Of Chemotherapy For Patients With Early Stage Breast Cancer
Express News | Assertio Holdings Inc - Rolvedon Shows 1.8 Days to Neutrophil Count Recovery
Express News | Assertio Holdings Inc - No New Safety Signals Identified in Rolvedon Trial
Express News | Assertio Announces Results of Rolvedon® (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study
Assertio Holdings: Schwichtenberg Currently Serves as Chief Comml Officer >ASRT
Assertio: Schwichtenberg to Identify Synergies, Innovative Strategies, New Rev Streams >ASRT
Express News | Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as Cco
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO
Beam Therapeutics Picks Ironwood Pharmaceuticals Finance and Operations Chief as CFO
Express News | Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
Lake Street Sticks to Its Buy Rating for Assertio Therapeutics (ASRT)
Assertio Holdings Analyst Ratings
H.C. Wainwright Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $4